

Resource Summary Report

Generated by RRID on Aug 11, 2026

Brilliant Violet 605(TM) anti-human CD39

RRID:AB_2750430

Type: Antibody

Proper Citation

BioLegend Cat# 328236, RRID:AB_2750430

Antibody Information

URL: http://antibodyregistry.org/AB_2750430

Proper Citation: BioLegend Cat# 328236, RRID:AB_2750430

Target Antigen: CD39

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD39

Description: This monoclonal targets CD39

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone A1

Antibody ID: AB_2750430

Vendor: BioLegend

Catalog Number: 328236

Alternative Catalog Numbers: 328235

Record Creation Time: 20250819T205743+0000

Record Last Update: 20250819T212319+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD39.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD39.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang K, et al. (2024) Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer cell, 42(9), 1582.

Sudmeier LJ, et al. (2022) Distinct phenotypic states and spatial distribution of CD8+ T cell clonotypes in human brain metastases. Cell reports. Medicine, 3(5), 100620.

O'Connor RA, et al. (2021) T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer. Oncoimmunology, 10(1), 1940675.